Navigation Links
NovaBay Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results
Date:8/14/2009

Ended inception) to June 30, June 30, June 30, 2008 2009 2008 2009 2009 (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) REVENUE License and collaboration revenue $1,442 $2,357 $2,933 $4,968 $19,136 EXPENSES Operating Expenses: Research and development 2,371 1,444 5,246 2,805 27,812 General and administrative 1,575 1,191 3,031 2,769 19,734 Total operating expenses 3,946 2,635 8,277 5,574 47,546 Interest expense (24) (20) (49) (43) (188) Other income (expense), net 118 9 306 42 1,417 Total Other income (expense), net 94 (11) 257 (1) 1,229 Net loss before income taxes (2,410) (289) (5,087) (607) (27,181) Provision for income taxes 2 14 Net loss $(2,410) $(289) $(5,089) $(607) $(27,195) Net loss per share: Basic and diluted $(0.11) $(0.01) $(0.24) $(0.03) Shares used in per share calculations: Basic and diluted 21,334 21,931 21,311 21,775


'/>"/>
SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. NovaBay(R) Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development
2. NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
3. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
4. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
5. NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
6. Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
7. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT
8. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
9. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
11. Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 The Oklahoma tornado left ... ravage, the mayor of Moore, one of the heavily damaged ... a report from cnn.com. Reaching out to also be of ... and Safe Shield to counter the looming mold problem. , ... May 22, 2013, caused 24 deaths, My Cleaning Products shared. ...
(Date:5/23/2013)... 24, 2013 Die Übersetzungen wurden ... Bei der englischen Version handelt es ... % der Teilnehmer einer groß angelegten Asthmaumfrage halten ihren ... GINA [*] -Definition [1] als kontrolliert gelten können ... generell einer von vier Denkweisen zugeordnet werden können, die ...
(Date:5/23/2013)... 23, 2013  BioScrip, Inc. (NASDAQ: BIOS ... the Jefferies 2013 Global Healthcare Conference to be held ... Richard Smith , President ... , Chief Financial Officer, will present on Monday, ... About BioScrip BioScrip, Inc. provides ...
(Date:5/23/2013)... Patheon Inc ., a leading ... global pharmaceutical industry, will host a complimentary webinar on ... on Tuesday, June 4, 2013 at 11 a.m. Eastern ... to comply with regulations for cleaning validation. Many ... underpinning and little evaluation of risk. Some companies ...
Breaking Biology Technology:Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2
... States and Canada and Monetary Damages, SAN ... medical device company focused on the treatment of ... infringement lawsuits,against CryoCath Technologies Inc., one in the ... and one in Canada., The lawsuits allege ...
... a,drug and diagnostic discovery company, today announced that ... Diagnostics and Genomic,Services Unit and the Therapeutics Unit., ... recent progress in core,programs have laid the foundation ... market. John Jaskowiak has been appointed as Head ...
... to Serve as rEEG(R) ,Center of Excellence, Advancing Performance in ... Patient Outcomes, Costs and Convenience, ... Bulletin Board: CNSO) announced today that it has completed the,previously ... Colorado. The Company also announced,that Daniel A. Hoffman, MD has ...
Cached Biology Technology:CryoCor Files Patent Infringement Lawsuits Against CryoCath 2CryoCor Files Patent Infringement Lawsuits Against CryoCath 3ExonHit Builds A New Organisation 2ExonHit Builds A New Organisation 3ExonHit Builds A New Organisation 4CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer 2CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer 3
(Date:5/23/2013)... with autologous cord blood. Following a cardiac arrest with ... been in a persistent vegetative state with minimal ... the cord blood containing stem cells, the symptoms improved ... speak simple sentences and to move. "Our findings, along ... doubts about the effectiveness of the new therapy", says ...
(Date:5/22/2013)... U.S. Forest Service scientists are part of "Landscapes of ... TKF Foundation, will examine how collaborative planning and stewardship ... tragedy. , The TKF Foundation announced today that Landscapes ... grant funding. In addition to research on the role ... resiliency, the 3-year, $585,000 grant will contribute to the ...
(Date:5/22/2013)... acids in fish oil have long been thought to ... Heart Association currently recommends eating at least two servings ... omega 3s. However, the mechanism behind this protective effect ... led by Jason R. Carter of Michigan Technological University ... fish oil might specifically counteract the detrimental effects of ...
Breaking Biology News(10 mins):First successful treatment of pediatric cerebral palsy with autologous cord blood 2'Landscapes of Resilience' to study how people use nature as a source of recovery 2Fish oil may help the heart beat mental stress 2
... a component of salt, are elevated in many urban streams ... government study. Chloride levels above the recommended federal criteria ... 40 percent of urban streams tested. The study was ... chloride can inhibit plant growth, impair reproduction, and reduce the ...
... WHO: ,The American Association of Pharmaceutical Scientists ... 12,000 members employed in industry, academia, government and ... provides a dynamic international forum for the exchange ... to public health. AAPS offers timely scientific programs, ...
... NiKem Research is pleased to announce that it ... of its bioanalysis facilities to further extend its drug discovery ... high quality cost-effective bioanalytical support both for its in ... services associated to various drug discovery programs and as a ...
Cached Biology News:Chloride found at levels that can harm aquatic life in urban streams of the Northern US 2AAPS and PhRMA co-sponsor stability workshop 2NiKem Research receives certification for GLP Bioanalysis 2
RAT ANTI MOUSE METALLOPHILIC MACROPHAGES...
S. O'Hare & C.K. Atterwill • In vitro toxicity techniques for regular lab use. Ex vivo techniques are also covered with the aim of reducing and refining the use of animals in the future....
Form: Ready to use Applications: ELISA...
Form: Ready to use Applications: ELISA...
Biology Products: